In patients with IgA nephropathy, RASi Use Is Associated with Better Survival and a Lower Risk of ESKD.

Published Date: 14 Mar 2024

With IgA Nephropathy, RASi Use Is Associated with Better Survival and a Lower Risk of ESKD.

Read Full News

Latest News

Deep Dive: The Evolving GLP-1 Class Overview

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

First-in-Class Drug Approved for IgA Nephropathy

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Navigating New Guidelines in IgA Nephropathy

FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

Todays Updates

Many Clinical Paths Are Open to NPs. Here’s Help in Picking

‘A strength of the nurse practitioner profession is its versatility,’ one expert says.

Nurses Speak Out on Burnout, Mandatory Overtime, and Burning the Candle at Both Ends

Emotionally drained, sleep-deprived, and skipping meals to keep up: what nurse leaders say needs to change to prevent burnout.

Most Family Physicians Struggle With After-Hours Admin Work

Most family physicians face heavy administrative burden, but improved electronic health records and staff support may help to ease some of the load.

'Just Bloating': Stop Dismissing This Common GI Complaint

Bloating is one of patients' most common gastrointestinal complaints. Dr Alicia Muratore kicks off this six-part series by asking why bloating is often treated as an afterthought.

S1 Episode 4: Urinary Tract Infections and Sexual Function

Drs Anne Lenore Ackerman and Rachel S. Rubin discuss urinary tract infections, sexual function, quality of life, and the importance of patient education.

Immunotherapy Promises New Era in Cancer Prevention

Prof David Kerr explores whether PD-1 inhibitors and targeted vaccines can regress polyps and prevent secondary cancers in Lynch syndrome.

HF Hospitalizations and Telehealth Coverage Parity Laws

State telehealth coverage parity laws require private insurers to cover outpatient telehealth visits increasing access for HF patients. This analysis examines whether this affected clinical outcomes.

Todays Updates

Many Clinical Paths Are Open to NPs. Here’s Help in Picking

‘A strength of the nurse practitioner profession is its versatility,’ one expert says.

Nurses Speak Out on Burnout, Mandatory Overtime, and Burning the Candle at Both Ends

Emotionally drained, sleep-deprived, and skipping meals to keep up: what nurse leaders say needs to change to prevent burnout.

Most Family Physicians Struggle With After-Hours Admin Work

Most family physicians face heavy administrative burden, but improved electronic health records and staff support may help to ease some of the load.

'Just Bloating': Stop Dismissing This Common GI Complaint

Bloating is one of patients' most common gastrointestinal complaints. Dr Alicia Muratore kicks off this six-part series by asking why bloating is often treated as an afterthought.

S1 Episode 4: Urinary Tract Infections and Sexual Function

Drs Anne Lenore Ackerman and Rachel S. Rubin discuss urinary tract infections, sexual function, quality of life, and the importance of patient education.

Immunotherapy Promises New Era in Cancer Prevention

Prof David Kerr explores whether PD-1 inhibitors and targeted vaccines can regress polyps and prevent secondary cancers in Lynch syndrome.

HF Hospitalizations and Telehealth Coverage Parity Laws

State telehealth coverage parity laws require private insurers to cover outpatient telehealth visits increasing access for HF patients. This analysis examines whether this affected clinical outcomes.

Latest News

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

News All Time

APOL1 Gene and Focal Segmental Glomerulosclerosis

Genetic variants tied to increased risk are only found in those of African decent

Make the Diagnosis: Chest Pain, Dyspnea, Palpitations, and More: What’s Her Diagnosis?

A 45-year-old woman presented to the emergency department with complaints of chest pain, heart palpitations that developed earlier that day, and dyspnea that began 3 days prior and had progressed. Can you diagnose the patient?

Rewriting What We Know About Kidney Transplant Rejection

Rewriting What We Know About Kidney Transplant Rejection

First Oral Carbapenem Approved for Complicated UTIs

Tebipenem pivoxil proved noninferior to IV imipenem-cilastatin in hospitalized patients

How Did a Patient Survive a Decade With Metastatic RCC?

Surgery had beneficial role

360 Dead in Outbreak; McConnell Still Hospitalized? FDA Rejects Kidney Disease Drug

Health news and commentary gathered by MedPage Today staff

US FDA Declines to Approve Unicycive's Kidney Disease Drug

Unicycive Therapeutics said on Tuesday the U.S. drug regulator has declined to approve its drug to ⁠treat elevated phosphate levels in chronic kidney disease patients on...

The Chatbot Will See You Now: A Crisis in Trust?

When healthcare feels out of reach, Europe’s patients are turning to AI for answers — and sometimes for the confidence to medicate themselves.

Extended-Release Febuxostat Beats Standard Drug for Gout

A new 24-hour version of febuxostat lowers uric acid levels significantly better than the standard drug for patients with severe gout, though it may carry a higher risk of serious side effects.

Mineralys' Pill Cuts Blood Pressure in Kidney Disease Patients

Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chronic kidney disease, according to new data presented ⁠at a major European...

Project Aims for Awareness of APOL1-Mediated Kidney Disease

The EMBARK Awareness initiative is working to raise awareness of APOL-1 mediated kidney disease among high-risk populations and medical trainees.

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Recommended News For You

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

Small Renal Mass Surveillance Does Not Affect Nephron-Sparing Surgery.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.

Research identifies nearly 200 potential breast carcinogens in food packaging materials

EHA: European Hematology Association

BMTs that are "half-matched" are effective in treating severe sickle cell disease.

Recommended Articles For You

Everything You Need to Know About Leiomyomas: A Comprehensive Guide  

Gene Therapy for Hemophilia: A New Hope on the Horizon 

Understanding Fibrosarcoma: What You Need to Know  

Innovative Marketing Strategies for Oncology Drugs: A Clinician’s Take on Digital and B2B Trends 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When Should Immunocompromised Individuals Receive a COVID Booster?

2.

Home Screening Appeals to Women Facing Healthcare Barriers

3.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

4.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

5.

Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents

1.

Rehabilitation After Organ-Conserving Cancer Surgery

2.

Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection

3.

Artificial Intelligence for Bone Marrow Cellular Ecosystem Modeling

4.

Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes

5.

Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Navigating the Complexities of Ph Negative ALL - Part XIII

2.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

5.

CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot